Isocitrate dehydrogenase 1 (IDH1) mutations are the most frequent genetic alteration in World Health Organization (WHO) grades II-III glioma and in secondary glioblastoma, now known as IDH mutant glioma or WHO grade IV, IDH mutant glioblastoma. 1 Genetic alteration in IDH2 is less frequent and mutually exclusive with mutations in IDH1. 2,3 IDH1/2 mutations have also been observed in acute myeloid leukemia (AML) and sporadic chondrosarcoma, and at lower frequency in cholangiocarcinoma, melanoma, and anaplastic thyroid cancer. 4 IDH1 mutations in gliomas and AML have, thus far, only been found at residue R132, which is most commonly mutated to a histidine. Mutations 
activity, resulting in generation of D-2-hydroxyglutarate (2-HG) from α-ketoglutarate (aka 2-oxoglutarate). 2-HG competitively inhibits α-ketoglutarate dependent dioxygenases, including collagen prolyl 4-hydroxylase, prolyl hydroxylases, and the ten-eleven translocation family of DNA hydroxylases, leading to alteration in numerous cellular processes as well as a distinct pattern of genomic hypermethylation, termed glioma cytosine-phosphateguanine (CpG) island methylator phenotype (G-CIMP). 4, 5 5-Azacytidine (5-aza) is currently approved for the treatment of myelodysplastic syndrome and is in clinical trials for solid tumors. 5-Aza is a nucleoside analogue, which covalently binds to DNA methyltransferase 1 (DNMT1), inducing proteasomal degradation and inhibiting methylation of DNA. 6 Noncytotoxic doses of DNA demethylating agents induce an antitumor memory response in breast cancer and leukemia, suppressing cancer stem cell-like subpopulation growth. 7 Recently, it has been found that DNA demethylating agents (5-aza and decitabine) slow tumor growth and induce cell differentiation in subcutaneous IDH1 R132H mutant gliomas in vivo. 8, 9 In this study, we sought to evaluate the mechanism of 5-aza induced tumor growth reduction and to evaluate the combination of 5-aza and temozolomide (TMZ) in IDH1 R132H preclinical models. We showed that IDH1 R132H mutant glioma treated with 5-aza is associated with cell senescence and increased expression of astrocyte lineage marker. In vivo, single agent 5-aza treatment extends survival in IDH1 R132H but not in IDH1 wild type (wt) glioma models. Survival benefit is additionally enhanced in combination with the standard-of-care agent TMZ. Collectively the evidence in this preclinical study supports a combination strategy of 5-aza and TMZ to reduce IDH1 mutant glioma growth.
Materials and Methods
Reagents and Cell Culture 5-Aza (Sigma Aldrich), TMZ, Z-Vad-FMK (Cayman), and AGI-5198 (Apexbio) were diluted in dimethyl sulfoxide. Human U87, U251, D54, and mouse glioma GL261 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Gemini BioProducts). BT142, TS603, JHH520, and Br23C glioma cells were cultured with Neurobasal serum-free media supplemented with 10 ng/mL basic fibroblast growth factor, 20 ng/ mL epidermal growth factor (Peprotech), and 0.0002% heparin (Stemcell Technologies). All cells were maintained in a humidified incubator at 5% CO 2 and 37°C. Detailed materials and methods are available as Supplementary information.
Cell Viability, Neurosphere Formation Assay, 5-Bromo-2ʹ-Deoxyuridine Incorporation Assay, and Drug Synergism Cell viability was assessed using an alamarBlue cell proliferation assay (ThermoFisher Scientific) as instructed by the manufacturer. Briefly, viable cells were plated in 96-well black flat-bottom plates and treated with the indicated drug concentration. Fluorescence was read in a Victor-3 automated plate reader (PerkinElmer). Half-maximal inhibitory concentration (IC 50 ) was calculated using GraphPad Prism 5.0. For the neurosphere formation assay, single viable cells were plated in 96-well plates in 200 µL serum-free media, treated with 5-aza, and neurospheres were counted 12 to 14 days after drug exposure. Four days after 5-aza and TMZ exposure, bromodeoxyuridine (BrdU) incorporation assay was conducted according to manufacturer's instruction (Roche). Effects of drug combination were calculated using CompuSyn Software 10 and Combenefit Software. 11 Senescence-Associated β-Galactosidase Staining Seven days after 5-aza treatment, cells were washed with phosphate buffered saline (PBS), fixed with paraformaldehyde 4% at room temperature, and incubated with X-gal solution (0.1% X-gal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM sodium chloride, and 2 mM magnesium chloride in 40 mM citric acid/sodium phosphate solution, pH 6.0) for 16 hours at 37°C.
Western Blot
Total protein lysates were extracted using radioimmunoprecipitation assay buffer (Sigma Aldrich) containing protease and phosphatase inhibitor cocktails (ThermoFisher Scientific). Protein concentration was measured using the bicinchoninic acid protein kit assay (ThermoFisher). Proteins were separated by electrophoresis on 4-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membrane (Bio-Rad). Membranes were blocked in 5% nonfat milk in PBS containing 0.1% Tween. The following primary antibodies were used: cleaved poly(ADP-ribose)
Importance of the Study
IDH1 R132H mutation is the most frequent genetic alteration in grades II-III gliomas, which eventually progress to secondary glioblastoma. IDH1 R132H mutant tumors are characterized by a distinct hypermethylated DNA phenotype, which could render IDH1 R132H mutant tumors preferentially sensitive to epigenetic modulation. Here, we showed that 5-aza, a DNA demethylating agent, reduces cell growth and extends survival in IDH1 R132H glioma cells. 5-Aza efficacy was further extended in combination with TMZ in vitro and subcutaneous and orthotopic IDH1 R132H glioma models. Therefore, we provide a biological basis and preclinical evidence for combination strategy of 5-aza and TMZ to reduce IDH1 R132H glioma growth.
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polymerase (PARP) Asp214, PARP, X-linked inhibitor of apoptosis protein (XIAP), B-cell lymphoma 2 (BCL2), BCL2-associated X protein (BAX), BCL2 antagonist killer (BAK), P21, P27, glial fibrillary acidic protein (GFAP; Cell Signaling Technologies), cyclin D1 (Abcam), DNMT1 (New England Biolabs), actin (Sigma), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology). The antigen-antibody complexes were visualized using a horseradish peroxidase (HRP)-conjugated secondary antibody (Invitrogen Life Technologies) and enhanced chemiluminescence system (Thermo Scientific).
Immunohistochemistry
Immunohistochemistry (IHC) analysis was performed on formalin-fixed paraffin-embedded sections. Immunodetections of Ki-67 (Dako) and GFAP (Cell Signaling) were performed on 5 μm sections. Tissue sections were sequentially deparaffinized, rehydrated, and antigen unmasked by boiling the sections in antigen retrieval citrate solution (Biogenex) was performed. Next, sections were blocked and incubated with primary antibody, followed by incubation with biotinylated secondary antibody and streptavidin-conjugated HRP (Super Sensitive Detection System, Biogenex). Sections were stained with 3ʹ3-diaminobenzidine chromogen and counterstained with Gill's hematoxylin.
Real-Time Quantitative PCR, Chromatin Immunoprecipitation, and Nucleosome Position Assay Total RNA was extracted using the High Pure RNA isolation kit (Roche). The first strand of cDNA was generated in the presence of oligodeoxythymidine and Superscript III Reverse Transcriptase (Invitrogen Life Technologies). Real-time quantitative polymerase chain reaction (qPCR) amplification was performed in duplicate using SsoFast Evagreen Supermix (BioRad) in the CFX96 Real-Time System (BioRad). Gene expression was normalized to the GAPDH; similar results were obtained with TBP and RPL13A endogenous control. Data were calculated using the 2-ΔΔ CT method and are presented as the fold change relative to the control sample. 12 Chromatin immunoprecipitation (Chip) was performed using the Agarose Chip Kit (Thermo Scientific) according with manufacturer's protocols. Briefly, 2 × 10 6 cells were fixed with 1% formaldehyde and chromatin was immunoprecipitated overnight with H3K27me3, H3K4me2 (Abcam), H3K4me3, and normal rabbit immunoglobulin G (Cell Signaling). Immunoprecipitated DNA was amplified using SsoFast Evagreen Supermix in triplicate. For the isolation of nucleosome-associated DNA we used the EZ nucleosomal DNA prep Kit (Zymo). Genomic and microccocal digested DNA was used for qPCR using SsoFast Evagreen Supermix. Primers were designed to cover the proximal promoter region of GFAP with amplicons averaging 90 ± 10 bp in size. The protection value set for each amplicon corresponds to the fold enrichment of that amplicon in the mononucleosomal DNA when compared with the undigested sample. 13 Oligonucleotide sequences are given in Supplementary  Tables 1, 3 , and 4.
Animal Studies
All animal protocols and procedures were performed in accordance with the Johns Hopkins Animal Care and Use Committee guidelines. Female athymic nude mice (6-8 weeks) purchased from Charles River Laboratories were kept in a pathogen-controlled environment with access to food and water ad libitum. Flank and orthotopic xenografts were performed as previously described. 8, 14 Tumor volume was determined by caliper measurements once a week according to the following formula: length × width 2 × 0.5. BT142 cells (3 × 10 5 ), JHH520 (3 × 10 5 ), and Br23C (1.5 × 10 5 ) were orthotopically implanted in nude mice fixed in a stereotactic frame. 14 Mice were randomized and treatment was initiated 5 days after tumor implantation. TMZ was diluted in PBS immediately before treatment. 5-Aza was diluted in sterile saline. Animals were monitored daily and euthanized in accordance with the Johns Hopkins Animal Care and Use Guidelines.
Statistical Analysis
Statistical analysis was performed by GraphPad Prism 5.0. The data were expressed as mean ± standard error. In vitro data represent one independent experiment in 3-4 replicates, performed at least 3 times to confirm reproducibility. Student's t-test was used to compare 2 means. One-way or 2-way ANOVA was used for multiple comparisons when appropriate. Log-rank (Mantel-Cox) test was used to analyze survival curves. P < 0.05 was considered statistically significant.
Results

5-Aza Reduces Cell Growth and Induces Senescence-Associated β-Galactosidase in IDH1 R132H Mutant Glioma Cells
We conducted cell viability analysis in adherent and suspension glioma cells treated with 5-aza. The IC 50 of 5-aza values ranged from 2.7 to 15.7 µM (Table 1) . No difference in average IC 50 values was observed between suspension and adherent cells, and between IDH1 mutant and IDH1 wt cells. Reduction of DNMT1 protein expression was dose-dependent in JHH520 and Br23C cells and consistently decreased in TS603 and BT142 after 3 days of 5-aza treatment (Fig. 1A) . DNA 5-mC was decreased after 5-aza exposure in BT142 cells (Supplementary Figure 1A) .
Treatment of cells with 5-aza increased cleaved PARP only in IDH1 wt cells (Fig. 1A) . 5-Aza treatment reduced neurosphere formation in all glioma cells, independent of IDH1 genotype (Fig. 1B) . Cell proliferation was also reduced after 5-aza exposure in all glioma tumorspheres (Supplementary Figure 1B) . To gain further insights about the cell growth reduction in glioma cells, we performed a protein expression analysis for apoptosis and cell cycle regulators. No modulation in apoptosis-related proteins (BAK, BCL2, and XIAP) were observed in glioma cells. BAX was slightly upregulated in U251 following 5-aza treatment. Cyclin D1 dose-dependent reduction was observed in U251, TS603, and JHH520 cells after 5-aza treatment. P21 protein expression increased in TS603 and JHH520 and P27 protein expression was markedly increased in JHH520, but slightly increased in TS603 and BT142 (Fig. 1C ). In addition, 5-aza treatment in BT142 cells upregulates in a dose-dependent fashion the gene expression of the tumor suppressors cyclin-dependent kinase inhibitor 1B (CDKN1B) and CDKN2A (Supplementary Figure 1C) . Pan-caspase inhibitor (Z-Vad-FMK) partially restores 5-aza-mediated growth reduction in JHH520 cells (Fig. 1D) . Taken together, it seems likely that other mechanisms not associated with cell death are reducing cell growth in IDH1 R132H cells. Indeed, 7 days after 5-aza exposure we observed a markedly increased senescence-associated β-galactosidase (SA β-gal) stain in glioma tumorspheres cultured in serum-free media (Fig. 1E) . Cell senescence is often associated with a specific senescence-associated secretory phenotype. A variety of secreted factors comprise the senescence-associated secretory phenotype, including pro-inflammatory cytokines, growth factors, chemokines, and proteases, which in turn regulate microenvironment and cell growth. 15 BT142 treated with 5-aza increased the gene expression of senescence markers IL6, IL1A, and CXCL8 (Supplementary Figure 1C) .
Recently, several IDH1/2 mutant enzyme inhibitors have been developed and some preclinical data showed survival benefit in mouse models. 16 We tested the combination of AGI-5198 and 5-aza in vitro and no impact in cell proliferation was observed (Supplementary Figure 2) . Similar data were observed in IDH1 R132H mutant glioma cells treated with AGI-5198 as single agent, as well as in combination with decitabine, a DNA demethylating agent. 9,17
5-Aza Induces Transcriptional Activation of GFAP in IDH1 R132H Mutant Glioma Cells
It has been showed that release the blocked differentiation and malignant cell growth reduction induced by IDH1/2 inhibitors and epigenetic reprogramming are potential therapies for IDH mutant glioma and leukemia. 16, 18 In IDH1 R132H glioma cells increased astroglial differentiation markers, including GFAP, and release the differentiation blocked induced by epigenetic modulation have been showed with DNA demethylating agents (5-aza and decitabine) and IDH1 R132H inhibitors. 8, 9, 16 However, the mechanism of GFAP induction by epigenetic modulation is not completely known in IDH1 mutant cells. Messenger RNA levels of GFAP increased after 3 days of 5-aza treatment in TS603 and BT142 IDH1 R132H mutant cells, but not in IDH1 wt cell JHH520 ( Fig. 2A) . Other astrocyte (ALDH1L1), oligodendrocyte (CNP, CSG, SPY, and CA2), neural (TUBB3), and stem cell (MSI and SOX2) markers were not modulated by 5-aza treatment in both IDH1 wt and IDH1 R132H mutant glioma cells. Previous studies have been shown that one CpG island is located between exons 5-6, but it is not associated with transcriptional control in glioma cells. 19 DNA demethylating agents also modulate histone methylation known to be functionally associated in gene expression control. 20 It has been described that some specific regions in GFAP promoter are important in control GFAP gene expression. 21 Therefore, we designed primer sets to map part of this region and the GFAP transcription start site, regions A to C cover around −1715 bp to −1597 bp and regions D to E cover region −55 bp to +407 bp in GFAP gene (Fig. 2B) . H3K27me3 is associated with transcriptional repressed genes. On the other hand, H3K4me2 and H3K4me3 modified are associated with transcriptional active genes. Regions A and B examined by qPCR showed enriched levels of H3K27me3 after 5-aza treatment, while H3K4me2 showed enrichment in region B (Fig. 2B) . Transcription is also associated with chromatin modulation with constitutively expressed genes exhibiting "open" chromatin compared with transcriptional repressed genes. Overlapping primer sets were designed to cover the GFAP promoter region from approximately the −1700 to −1100 bp and qPCR was conducted to map the nucleosome occupancy after DNA microccocal digestion (Fig. 2C) . High resolution map of nucleosome occupancy and location at genomic locus is an assay to targeted nucleosome mapping and can be obtained by scanning qPCR. 13 5-Aza showed a dose-dependent reduction nucleosome occupancy in all regions examined, but with marked reduction in regions with higher histone modifications (−1657 to −1529 bp) (Fig. 2C) , suggesting a more open chromatin and likely more transcriptional activity. The region with open chromatin correlates with histone modifications in 5-aza treated cells (regions A and B) (Fig. 2C) and previous studies pointed out an important CG dinucleotide rich region in GFAP gene expression control. 21 To analyze the CG dinucleotide methylation status in the GFAP promoter region (−1695 to −1440), we sequenced bisulfite converted DNA from TS603 cells treated with 5-aza. DNA bisulfite converted sequence showed little CG dinucleotide methylation in control and in 5-aza treated cells. We also confirmed this observation by methylation-specific PCR covering this region in TS603 cells treated with 5-aza (Supplementary Figure 3) . We showed higher GFAP protein expression in TS603 IDH1 R132H mutant cells after 5-aza treatment, but not in JHH520 IDH1 wt cells (Fig. 2D) . Furthermore, TS603 cells with stable DNMT1 gene silencing reduced DNMT1 mRNA and protein expression with concomitant increase in GFAP mRNA Data are mean ± SEM of at least 3 independent experiments performed in quadruplicate. ND: not determined.
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and protein levels ( Fig. 2E and 2F) . Finally, to test the causality between 5-aza-mediated GFAP induction and glioma cell proliferation, we transfected TS603 cells with small interfering (si)RNA-mediated GFAP gene silencing, as well as mock and nontarget control, and treated cells with 5-aza. GFAP protein expression reduction was confirmed by western blot analysis, TS603 cells transfected with siRNA-mediated GFAP gene silencing abrogates 5-aza and induces GFAP protein expression. TS603 transfected with siGFAP and treated with 5-aza did not modulate cell proliferation (Supplementary Figure 3D) .
5-Aza Extends Survival in IDH1 R132H Mutant Cells In Vivo
Encouraged by our in vitro data showing the effect of DNA demethylating agent on cell growth, we orthotopically implanted JHH520 IDH1 wt, Br23C IDH1 wt cells, and BT142 IDH1 R132H mutant cells in nude mice and examined if 5-aza could extend survival in vivo. 5-Aza treatment provided survival benefit in the IDH1 R132H mutant, but not JHH520 and Br23C IDH1 wt tumors (Fig. 3A) . This effect was observed in the BT142-luc model, where Relative nucleosome occupancy 
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5-aza treatment reduced tumor burden by 82% compared with control at 70 days (Fig. 3B) . Morphological analysis of BT142 cells revealed dense cellular tissue, extensive microvasculature, and hyperchromatic cells (Fig. 3C) . Immunohistochemistry showed that BT142 vehicletreated group tissue were intensively positive for Ki-67, a cell proliferation marker. 5-Aza treatment decreased Ki-67 positive cells, suggesting that 5-aza survival benefit is associated with reduced tumor growth. GFAP protein expression was augmented with 5-aza treatment (Fig. 3C  and 3D ).
5-Aza Reduces IDH1 R132H Growth in Combination with TMZ In Vitro
5-Aza and TMZ as single agents reduce IDH1 R132H glioma cell growth, and the combination of 5-aza and TMZ further reduce cell growth (Fig. 4A) . To quantify the synergism between 5-aza and TMZ we used the Chou-Talalay algorithm. 10 Cell viability was normalized to their correspondent vehicle controls for each treatment condition and used to calculate the combination index (CI). Synergism between 5-aza and (D) Ki-67 labeling index from BT142 intracranial tumors (n = 3 mice/group). **P < 0.01.
TMZ was observed with lower dose of 5-aza (0.5 and 1 µM) and with TMZ doses observed in glioblastoma patients (10 to 100 µM) (Supplementary Figure 3) . Different drug combination models (highest single agent, bliss independence, and Loewe additivity) were used to confirm the synergism between 5-aza and TMZ (Supplementary Figure 4) . 5-Aza and TMZ reduced BT142 cells in S phase as single agents, and drug combination further reduced cells in S phase exposure with both drugs compared with single agents (Fig. 4B ). In addition, drug combination increased cleaved PARP and pH2A.X protein expression in BT142 cells (Fig. 4C and 4D ). It has shown that TMZ induces autophagy and in combination with nicotinamide phosphoribosyltransferase inhibitors further reduces IDH1 mutant cell growth, 
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through an autophagy-related mechanism. 22 To test if autophagy plays a role in IDH1 R132H glioma we add chloroquine to 5-aza plus TMZ and analyzed cell proliferation and LC3II protein expression, a marker of autophagy. 5-Aza single agent and 5-aza plus TMZ increased LC3II protein expression. However, combination of 5-aza plus TMZ with chloroquine did not reduce cell growth compared with respective controls (Supplementary Figure 5) . 
5-Aza Reduces Tumor Growth in Combination with TMZ in Subcutaneous and Orthotopic
IDH1 R132H Glioma Models
We next examined the impact of 5-aza in combination with TMZ in JHH273, an IDH1 R132H mutant glioma PDX model previously described by our group. 8 5-Aza plus TMZ slow tumor growth compared with single agent treatments (Fig. 5A) and no difference was observed in mice body mass (Supplementary Figure 6A) . In order to determine whether demethylating agents would interfere with TMZ sensitivity due to O 6 -methylguanine-DNA methyltransferase (MGMT) demethylation, mice bearing JHH273 flank tumors were treated with 5-aza, TMZ, or a combination in varying sequence. Fig. 5B shows that single agent administration of 5-aza and TMZ both decrease tumor growth. Although TMZ administration before 5-aza provides superior tumor growth inhibition, pretreatment with 5-aza does not reverse sensitivity to TMZ but rather enhances tumor growth inhibition. This finding suggests that pretreatment of IDH1 R132H mutant tumors with DNA demethylating agent 5-aza does not abrogate sensitivity to TMZ and the combination may provide clinical benefit. JHH273 tumors showed a marked reduction in DNMT1 protein expression in the 5-aza single agent treated group and increase in GFAP protein expression ( Fig. 5C and 5D ). 5-Aza treatment also slightly reduced DNA 5-mC in JHH273 tumor (Supplementary Figure 6A) . Methylation-specific PCR showed a slight demethylation of MGMT promoter after 5-aza treatment in JHH273 tumor (Supplementary Figure 7B) . To expand on the data generated in the subcutaneous IDH1 R132H mutant PDX model, efficacy of 5-aza, TMZ, and combination was evaluated in the orthotopic IDH1 R132H glioma model BT142 (Fig. 5E) . No difference was observed in mice body mass treated with drug combination (Supplementary Figure 6B) . Consistent with previous findings (Fig. 3A) , single agent 5-aza was effective in the IDH1 R132H model (P = 0.002 vs control). Additionally, single agent TMZ was very effective (P = 0.0001 vs control and 5-aza) and the combination of TMZ with 5-aza had an additional benefit in the IDH1 R132H model, extending survival 53% more compared with TMZ as a single agent (P = 0.002 vs TMZ). Toxicity test showed no observable toxicity or statistical significance in mice body mass, and 5-aza, TMZ, and drug combination did not induce morphological changes in brain, kidney, heart, and liver (Supplementary Figure 6C and 6D ).
Discussion
The IDH1 or IDH2 mutation in gliomas defines a unique class of brain cancer that has a different clinical course, are driven in part by hypermethylation, and should be considered separately for therapeutic development. 23 In this study, we provide further preclinical and mechanistic evidence that targeting the epigenetic alterations brought on by an IDH mutation may form a basis for improved therapy of these tumors. The DNA demethylating agent 5-aza reduced cell growth and extended survival in 2 preclinical models of IDH1 mutant.
DNA demethylating agents reduce cell growth by several mechanisms, including cell cycle arrest, inhibition of cell cycle progression related protein expression, and inducing of cell death. 24 Transient low dose of DNA demethylating agents (5-aza and decitabine) consistently decrease breast and hematological tumors in preclinical models, through a mechanism that reactivates tumor suppressor gene expression and inhibits cell cycle progression. 7 Additionally, cancer cells treated with 5-aza and decitabine activates endogenous retroviruses, which in turn induces interferon response and apoptosis. 25, 26 Although 5-aza and decitabine showed DNA demethylating proprieties, 5-aza can also incorporate in RNA, while decitabine preferentially incorporates in DNA. 24, 27 These differential mechanisms of action have not been completely understood and could explain, at least in part, the variances in clinical efficacy of 5-aza and decitabine. Because the IDH1 mutation in glioma produces sustained pathological levels of 2-HG, we hypothesized that IDH mutant gliomas might respond better to a continuous 5-aza exposure. In IDH1 wt cells, 5-aza reduces cell growth by a mechanism associated with modulation of cell cycle-related proteins. Alternatively, in IDH mutant glioma cells, 5-aza treatment appears to induce cell differentiation, tumor suppressor induction, and senescence. Multiple mechanisms can trigger cell senescence and it is considered an important mechanism for preventing proliferation and suppressing tumor growth. 15 We also showed that GFAP transcription was induced only in IDH1 R132H cells with 5-aza treatment. This mechanism is likely not mediated entirely by DNA demethylation, since one CpG island located between exons 5 and 6 does not control gene expression in glioma cells and we did not observe CG dinucleotide demethylation after 5-aza treatment in a critical region of GFAP promoter. 21 However, a careful interpretation of CpG island and gene transcription should be taken into account in the 5-aza treated IDH1 R132H glioma cells context; several other CG dinucleotides have been associated with GFAP transcription regulation in glioma IDH1 wt. 19 We also cannot rule out additional regulation mechanisms (such as transcription factors) controlling GFAP gene expression in glioma cells. 5-Aza modulated histone modifications and nucleosome position, which likely participate in GFAP transcription control. In fact, histone methylation can form localized regions of active and inactive chromatin domain in the promoter region during normal development of astrocytogenesis demethylation, and histone modification in specific regions of GFAP promoters are essential to gene transcriptional induction. 21, 28, 29 The functional role of GFAP expression in glioma cells is not completely understood. SiRNA-mediated GFAP gene silencing did not rescue cell proliferation in IDH1 R132H glioma cells treated with 5-aza. It is likely that GFAP induction individually plays a minor role in IDH mutant glioma cell growth regulation, since several tumor suppressor genes are concomitantly upregulated after 5-aza treatment. It has been shown that antisense-mediated GFAP downregulation increased proliferation and invasion in GFAP positive glioma cells in vitro. 30 Conversely, stable or inducible GFAP protein overexpression in GFAP negative glioma cells reduces cell growth. 31, 32 However, this cell growth regulation by GFAP
